T1	PROC 44 66	Estudio de Seguimiento
T2	CHEM 703 710	ABT-450
#1	AnnotatorNotes T2	C3712108; ABT-450; Organic Chemical · Pharmacologic Substance
T3	CHEM 431 434	AAD
#2	AnnotatorNotes T3	C3653501; DIRECT ACTING ANTIVIRALS; Pharmacologic Substance
T4	DISO 240 251	hepatitis C
#3	AnnotatorNotes T4	C0019196; Hepatitis C; Disease or Syndrome
T5	PROC 1035 1059	consentimiento informado
#4	AnnotatorNotes T5	C0567423; Informed consent for procedure; Therapeutic or Preventive Procedure
T6	PROC 300 322	Estudio de seguimiento
T7	PROC 1157 1171	procedimientos
#5	AnnotatorNotes T7	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure | C0184661; Interventional procedure; Therapeutic or Preventive Procedure
T8	PROC 384 395	tratamiento
#6	AnnotatorNotes T8	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T9	PROC 477 513	estudios clínicos de fase 2 o fase 3
T10	PROC 522 533	tratamiento
#7	AnnotatorNotes T10	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T11	DISO 540 588	infección crónica por el virus de la hepatitis C
#8	AnnotatorNotes T11	C4736230; chronic hepatitis C due to hepatitis C virus genotype 1a; Disease or Syndrome | C4736234; chronic hepatitis C due to hepatitis C virus genotype 4; Disease or Syndrome
T12	DISO 618 629	Hepatitis C
#9	AnnotatorNotes T12	C0019196; Hepatitis C; Disease or Syndrome
T13	PROC 1452 1466	procedimientos
#10	AnnotatorNotes T13	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure | C0184661; Interventional procedure; Therapeutic or Preventive Procedure
T14	PROC 843 854	tratamiento
#11	AnnotatorNotes T14	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T15	PROC 873 888	estudio clínico
#12	AnnotatorNotes T15	C0008972; Clinical Research; Research Activity | C0008976; Clinical Trials; Research Activity
T16	PROC 1243 1254	tratamiento
#13	AnnotatorNotes T16	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T17	PROC 1471 1486	estudio clínico
#14	AnnotatorNotes T17	C0008972; Clinical Research; Research Activity | C0008976; Clinical Trials; Research Activity
T18	CHEM 855 858	AAD
#15	AnnotatorNotes T18	C3653501; DIRECT ACTING ANTIVIRALS; Pharmacologic Substance
T19	CHEM 712 719	ABT-333
#16	AnnotatorNotes T19	C3850285; ABT-333; Organic Chemical · Pharmacologic Substance
T20	DISO 590 593	VHC
#17	AnnotatorNotes T20	C0019196; Hepatitis C; Disease or Syndrome
T21	Observation 336 347	resistencia
#18	AnnotatorNotes T21	C3542449; Drug Resistance Status; Finding
T22	CHEM 722 729	ABT-267
#19	AnnotatorNotes T22	C3713322; ABT-267; Organic Chemical · Pharmacologic Substance
T23	CHEM 400 429	antivirales de acción directa
#20	AnnotatorNotes T23	C3653501; DIRECT ACTING ANTIVIRALS; Pharmacologic Substance
T24	DISO 786 789	VHC
#21	AnnotatorNotes T24	C0019196; Hepatitis C; Disease or Syndrome
T25	Date 12 16	2012
T26	Date 86 99	a largo plazo
T27	LIVB 103 112	pacientes
#22	AnnotatorNotes T27	C0030705; Patients; Patient or Disabled Group
T30	LIVB 449 456	sujetos
#23	AnnotatorNotes T30	C0681850; Study Subject; Group
T31	Duration 550 557	crónica
#24	AnnotatorNotes T31	C0205191; chronic; Temporal Concept
T32	LIVB 565 588	virus de la hepatitis C
#25	AnnotatorNotes T32	C0220847; hepatitis C virus; Virus
T34	LIVB 662 668	sujeto
#26	AnnotatorNotes T34	C0681850; Study Subject; Group
T35	Dose 681 699	al menos una dosis
T37	CONC 827 839	última dosis
T38	Neg_cue 935 937	no
T39	Duration 947 964	superior a 2 años
T40	LIVB 973 979	sujeto
#27	AnnotatorNotes T40	C0681850; Study Subject; Group
T41	LIVB 1203 1209	sujeto
#28	AnnotatorNotes T41	C0681850; Study Subject; Group
T42	Date 1238 1254	Post-tratamiento
T43	LIVB 1329 1341	investigador
#29	AnnotatorNotes T43	C0035173; Research Personnel; Professional or Occupational Group
T44	LIVB 1359 1365	sujeto
#30	AnnotatorNotes T44	C0681850; Study Subject; Group
T46	Date 1609 1614	día 1
T28	CHEM 1528 1553	producto en investigación
#31	AnnotatorNotes T28	C0013230; Investigational New Drugs; Pharmacologic Substance
A1	Assertion T39 Negated
A2	Status T9 History_of
A3	Status T2 History_of
A4	Status T19 History_of
A5	Status T22 History_of
A6	Status T14 History_of
A7	Status T18 History_of
A8	Status T17 History_of
A9	Status T15 History_of
#32	AnnotatorNotes T26	C0443252; Long-term; Temporal Concept
#33	AnnotatorNotes T9	C0282460; Phase 2 Clinical Trials; Research Activity | C0282461; Phase 3 Clinical Trials; Research Activity
#34	AnnotatorNotes T1	C3274571; Clinical Study Follow-up; Health Care Activity
#35	AnnotatorNotes T6	C3274571; Clinical Study Follow-up; Health Care Activity
T29	Observation 192 222	respuesta virológica mantenida
A10	Assertion T29 Negated
#36	AnnotatorNotes T29	C3888663; Sustained viral response; Finding
T33	Neg_cue 174 176	no
T36	Neg_cue 1366 1368	no
T45	Observation 1372 1394	idóneo para el estudio
A11	Assertion T45 Negated
#37	AnnotatorNotes T45	C1302261; Patient eligible for clinical trial; Finding (?)
R1	Negation Arg1:T38 Arg2:T39	
R2	Negation Arg1:T36 Arg2:T45	
R3	Negation Arg1:T33 Arg2:T29	
R4	Overlap Arg1:T1 Arg2:T26	
T47	Observation 137 167	respuesta virológica mantenida
#38	AnnotatorNotes T47	C3888663; Sustained viral response; Finding
R5	Experiences Arg1:T27 Arg2:T47	
R6	Experiences Arg1:T27 Arg2:T29	
R7	Experiences Arg1:T27 Arg2:T4	
R8	Overlap Arg1:T47 Arg2:T29	
R9	Overlap Arg1:T29 Arg2:T4	
T48	PROC 229 236	estudio
#39	AnnotatorNotes T48	C0008976; Clinical Trials; Research Activity
T49	Observation 371 395	respuesta al tratamiento
#40	AnnotatorNotes T49	C1319171; Medication response; Finding
R12	Used_for Arg1:T23 Arg2:T8	
R13	Used_for Arg1:T3 Arg2:T8	
R14	Overlap Arg1:T49 Arg2:T23	
R15	Overlap Arg1:T49 Arg2:T3	
R16	Experiences Arg1:T30 Arg2:T49	
R17	Experiences Arg1:T30 Arg2:T8	
R18	Experiences Arg1:T30 Arg2:T10	
R20	Overlap Arg1:T49 Arg2:T10	
R21	Causes Arg1:T32 Arg2:T20	
R22	Causes Arg1:T32 Arg2:T11	
R23	Has_Duration_or_Interval Arg1:T11 Arg2:T31	
R24	Experiences Arg1:T30 Arg2:T11	
R25	Experiences Arg1:T30 Arg2:T20	
R26	Experiences Arg1:T34 Arg2:T2	
R27	Experiences Arg1:T34 Arg2:T19	
R28	Experiences Arg1:T34 Arg2:T22	
R29	Has_Dose_or_Strength Arg1:T2 Arg2:T35	
R30	Has_Dose_or_Strength Arg1:T19 Arg2:T35	
R31	Has_Dose_or_Strength Arg1:T22 Arg2:T35	
T50	PROC 736 743;763 776	estudio de fase 2 o 3
#41	AnnotatorNotes T50	C0282460; Phase 2 Clinical Trials; Research Activity | C0282461; Phase 3 Clinical Trials; Research Activity
R32	Experiences Arg1:T34 Arg2:T24	
R33	Has_Dose_or_Strength Arg1:T18 Arg2:T37	
R34	Used_for Arg1:T18 Arg2:T14	
T51	CONC 903 912	inclusión
#42	AnnotatorNotes T51	C1512693; Inclusion; Qualitative Concept
R35	Before Arg1:T51 Arg2:T39	
R36	Before Arg1:T37 Arg2:T51	
R37	Before Arg1:T5 Arg2:T7	
T52	PROC 919 926	estudio
#43	AnnotatorNotes T52	C0008976; Clinical Trials; Research Activity
T53	Observation 1213 1254	completado el periodo de Post-tratamiento
R38	Experiences Arg1:T41 Arg2:T16	
R39	Before Arg1:T16 Arg2:T42	
A12	Status T52 History_of
T54	PROC 1269 1277	estudios
A13	Status T54 History_of
#44	AnnotatorNotes T54	C0008976; Clinical Trials; Research Activity
A14	Status T16 History_of
R42	Has_Quantifier_or_Qualifier Arg1:T44 Arg2:T45	
T55	Observation 1430 1466	incumplimiento de los procedimientos
#45	AnnotatorNotes T55	C0184543; Noncompliance with therapeutic regimen; Finding (?)
R44	Before Arg1:T55 Arg2:T45	
A15	Status T13 History_of
T56	PROC 1587 1594	estudio
#46	AnnotatorNotes T56	C0008976; Clinical Trials; Research Activity
T57	Observation 1565 1594	participación en este estudio
#47	AnnotatorNotes T57	C1278516; Patient participation status; Finding (?)
R45	After Arg1:T57 Arg2:T46	
R46	After Arg1:T28 Arg2:T46	
R47	Overlap Arg1:T21 Arg2:T23	
R48	Overlap Arg1:T21 Arg2:T3	
R10	Experiences Arg1:T30 Arg2:T21	
#48	AnnotatorNotes R33	(?)
#49	AnnotatorNotes T37	C1762893; Date last dose; Temporal Concept
A16	Experiencer T27 Patient
A17	Experiencer T30 Patient
A18	Experiencer T34 Patient
A19	Experiencer T40 Patient
A20	Experiencer T41 Patient
A21	Experiencer T43 Other
A22	Experiencer T44 Patient
